ArticleNeuroscience bulletin2013
Cysteine residues 87 and 320 in the amino terminal domain of NMDA receptor GluN2A govern its homodimerization but do not influence GluN2A/GluN1 heteromeric assembly.
Article in Neuroscience bulletin, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- The Extracellular Domains of GluN Subunits Play an Essential Role in Processing NMDA Receptors in the ER.Frontiers in neuroscience · 2021Review
- Huntingtin-Interacting Protein 1-Related Protein Plays a Critical Role in Dendritic Development and Excitatory Synapse Formation in Hippocampal Neurons.Frontiers in molecular neuroscience · 2017Article
- Serine 707 of APPL1 is Critical for the Synaptic NMDA Receptor-Mediated Akt Phosphorylation Signaling Pathway.Neuroscience bulletin · 2016Article
- Clustering of surface NMDA receptors is mainly mediated by the C-terminus of GluN2A in cultured rat hippocampal neurons.Neuroscience bulletin · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N-Methyl-D-aspartate receptors (NMDARs) play a central role in various physiological and pathological processes in the central nervous system. And they are commonly composed of four subunits, two GluN1 subunits and two GluN2 or GluN3 subunits. The different subunit compositions make NMDARs a heterogeneous population with distinct electrophysiological and pharmacological properties and thus with different abilities to conduct neuronal activities. The subunit composition, assembly process, and final structure of assembled NMDARs have been studied for years but no consensus has been achieved. In this study, we investigated the role of the amino terminal domain (ATD) of GluN2A in regulating NMDAR assembly. The ATD of GluN2A was first expressed in heterogeneous cells and the homodimer formation was investigated by fluorescent resonance energy transfer and non-reducing SDSPAGE electrophoresis. Each of the three cysteine residues located in the ATD was mutated into alanine, and the homodimerization of the ATD or GluN2A, as well as the heteromeric assembly of NMDARs was assessed by non-reducing SDSPAGE electrophoresis, co-immunoprecipitation and immunocytochemistry. We found that two cysteine residues, C87 and C320, in the ATD of the GluN2A subunit were required for the formation of disulfide bonds and GluN2A ATD homodimers. Furthermore, the disruption of GluN2A ATD domain dimerization had no influence on the assembly and surface expression of NMDARs. These results suggest that the two ATD domains of GluN2A are structurally adjacent in fully-assembled NMDARs. However, unlike GluN1, the homomerization of the ATD domain of GluN2A is not required for the assembly of NMDARs, implying that GluN2A and GluN1 play unequal roles in NMDAR assembly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.